Back to Archived News
Cytori Receives Key Patent for its Cosmetic & Reconstructive Surgery Product
Wednesday, October 01, 2008
Covers Methods in Using the Celution® System for Cell-Enhanced Reconstruction
San Diego, CA -- Cytori Therapeutics (Nasdaq: CYTX) today received U.S. Patent No. 7,429,488 (the ‘488 patent), which broadly protects the Company’s Celution® System-based methods of generating adipose tissue-derived stem and regenerative cell-enhanced fat grafts. Cell-enhanced fat grafts may be used in a variety of cosmetic and reconstructive surgery applications, including breast reconstruction following partial mastectomy, breast implant salvage, as well as facial and other cosmetic applications. The Celution 800/CRS System is currently available for sale in Europe and parts of Asia.
Receipt of the ‘488 patent, which runs until at least January 2024, is important to Cytori because it further strengthens the Celution System’s competitive position within the cosmetic and reconstructive surgery market. Part of Cytori’s strategy to create greater barriers-to-entry is to protect distinct applications of the Celution System. This allows Cytori to build additional layers of protection around U.S. Patent No. 7,390,484, which was recently issued to Cytori and covers the Celution System’s core technology. Additional patents have been filed around other Celution System applications, including cell banking, cardiovascular disease, spine and orthopedic repair, among others.
This patent broadly protects Cytori’s Celution 800/CRS System, which automates the method of creating a cell-enhanced fat graft. First, the Celution 800/CRS System processes stem and regenerative cells from a small amount of adipose tissue. Next, the Celution 800/CRS System mixes these cells with liposuctioned fat tissue. This forms the cell-enhanced fat graft, which may be used as a natural filler to reconstruct soft tissue defects.
Cytori’s intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes eight U.S. and international patents and over 120 applications pending worldwide. Combined with Cytori’s proprietary know-how, exclusive supply agreements, and instrumentation, greater barriers-to-entry are being created to offer what the Company believes is the only safe, high-quality and effective adipose tissue processing device.
Cytori’s (Nasdaq: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe and Asia Pacific into the reconstructive surgery market while the Celution® 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, statements regarding the private placement, the expected closing of the private placement, the number of additional shares that could be sold in connection with exercise of warrants issued in the private placement, a need for further financing, our plans for expanding commercialization of our Celution® 800/CRS System and for global marketing efforts for our Celution System-based StemSource® Cell Bank business, and other risks and uncertainties described under the heading "Risk Factors" in Cytori’s Securities and Exchange Commission filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Back to Archived News